Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer

Cisplatin resistance remains a major problem in the treatment of lung cancer. We have discovered that cisplatin resistant (CR) lung cancer cells, regardless of the signaling pathway status, share the common parameter which is an increase in reactive oxygen species (ROS) and undergo metabolic reprogr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Wangpaichitr, Medhi, Wu, Chunjing, Li, Ying Ying, Nguyen, Dan J.M., Kandemir, Hande, Shah, Sumedh, Chen, Shumei, Feun, Lynn G., Prince, Jeffrey S., Kuo, Macus T., Savaraj, Niramol
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564767/
https://ncbi.nlm.nih.gov/pubmed/28525376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17568
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires